The
global clot management devices market is growing significantly due to large
geriatric population and high incidences of cardiovascular diseases, such as
stroke and heart attacks. The increasing demand for
minimally invasive surgeries and massive unexplored clot
management devices market in the emerging economies are creating ample
opportunities for the growth of the global clot management devices market. The
advanced research and development facilities and new product developments by the major players
are supporting the demand for cost-effective and efficient clot management devices.
In the global clot management devices market, a trend
of increasing usage of percutaneous procedures for clot management has been
observed. Clot management refers to the treatment of patients with blood clots,
such as pulmonary embolism, arterial blood clots and deep vein thrombosis. Blood
clot or thrombus is formed by platelets and fibrin in blood to stop bleeding
from injured blood vessels. However, sometimes a blood clot is formed inside a
blood vessel even though when it is not required. This may lead to serious
medical consequences, such as deep vein thrombosis and pulmonary embolism. There
are several risk-leading factors, such as smoking, certain surgeries, inherited
blood clotting diseases, pregnancy, immobility, high cholesterol level and
certain heart diseases, which may cause blood clots.
The key players operating in the global clot management devices market are Applied Medical Resources Corporation, EKOS Corporation (a BTG International group company), St. Jude Medical Inc., Medtronic, Boston Scientific Corporation, Volcano Corporation, AngioDynamics, Johnson & Johnson Services Inc., Sorin Group, Bayer AG, Abbott, Stryker and Edwards Lifesciences Corporation.
No comments:
Post a Comment